Synlogic (NASDAQ:SYBX) PT Raised to $20.00 at Piper Jaffray Companies

Synlogic (NASDAQ:SYBX) had its price objective upped by Piper Jaffray Companies from $16.00 to $20.00 in a research note published on Monday morning, The Fly reports. They currently have an overweight rating on the biotechnology company’s stock.

Several other research firms also recently weighed in on SYBX. Wedbush reissued an outperform rating and set a $21.00 target price on shares of Epizyme in a research report on Wednesday, June 12th. Jefferies Financial Group cut their target price on CommVault Systems to $65.00 and set a buy rating on the stock in a research report on Tuesday, April 30th. They noted that the move was a valuation call. HC Wainwright set a $126.00 target price on AnaptysBio and gave the company a buy rating in a research report on Monday, June 24th. Chardan Capital set a $10.00 target price on Arcimoto and gave the company a buy rating in a research report on Friday, April 12th. Finally, Zacks Investment Research downgraded HEXO from a hold rating to a sell rating in a research report on Wednesday, May 15th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Synlogic has a consensus rating of Buy and an average price target of $20.00.

NASDAQ:SYBX opened at $7.72 on Monday. The company has a current ratio of 11.53, a quick ratio of 11.53 and a debt-to-equity ratio of 0.20. Synlogic has a 1 year low of $5.75 and a 1 year high of $14.59. The business has a 50 day moving average price of $8.25. The company has a market cap of $196.00 million, a P/E ratio of -3.80 and a beta of 2.42.

Synlogic (NASDAQ:SYBX) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.03. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.42 million. Synlogic had a negative return on equity of 38.93% and a negative net margin of 2,005.43%. On average, equities research analysts expect that Synlogic will post -2.09 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can boosted its holdings in Synlogic by 5,743.1% during the 1st quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 12,520 shares during the period. Rhumbline Advisers boosted its holdings in Synlogic by 45.7% during the 4th quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 6,820 shares during the period. Bank of New York Mellon Corp boosted its holdings in Synlogic by 12.1% during the 4th quarter. Bank of New York Mellon Corp now owns 56,774 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 6,129 shares during the period. Alps Advisors Inc. boosted its holdings in Synlogic by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 61,466 shares of the biotechnology company’s stock valued at $467,000 after acquiring an additional 2,658 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Synlogic by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 155,161 shares of the biotechnology company’s stock valued at $1,087,000 after acquiring an additional 16,591 shares during the period. Institutional investors own 81.89% of the company’s stock.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Read More: Index Funds

The Fly

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.